Slides
Page 1
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Click to edit Master text Analyst Day F e b r u a r y 1 0th , 2 0 2 6
Page 2
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 2 Disclaimer This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements, including, but not limited to statements regarding financial guidance, sales, revenue and operating expense estimates, adjusted EBITDA estimates, expectations regarding product utilization, product reimbursement rates, synergy estimates and timing, expectations and timing regarding clinical studies and development and expectations of CorMedix Therapeutics' product pipeline, results of the real-world studies, expectations regarding implementation and perceived benefits of CorMedix’s products, and estimates of total addressable market size. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix and in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this presentation. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Forward-looking statements involve estimates, expectations, projections, goals, forecasts, assumptions, risks and uncertainties. Actual outcomes or results may differ from anticipated results, sometimes materially. Factors that could cause actual results to differ include, but are not limited to: the strategies, plans and objectives of CorMedix Therapeutics (including it's growth strategy and corporate development initiatives); the status and timing of clinical studies, data analysis and communication of results; expectations regarding reimbursement rates, customer utilization, and other factors impacting the demand for CorMedix Therapeutics' products; the timing of regulatory approval of additional indications; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment; the ability of CorMedix Therapeutics to achieve the identified synergies; that operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers or suppliers) may be greater than expected following the acquisition of Melinta; the retention of certain key employees; the expected benefits and success of CorMedix Therapeutics’ products and product candidates; potential litigation relating to the transaction that could be instituted against CorMedix or its directors; rating agency actions and CorMedix Therapeutics’ ability to access short- and long-term debt markets on a timely and affordable basis; general economic conditions that are less favorable than expected; geopolitical developments and additional changes in international trade policies and relations, including tariffs; and the ability of our products and product candidates to compete effectively against current and future competitors.
Page 3
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Joe Todisco, Chairman & Chief Executive Officer 3 Introduction To CorMedix Therapeutics 2026 Analyst Day
Page 4
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 4 Agenda Topic Speaker(s) Timing (est’d) Welcome & Agenda Matt David, M.D. Chief Business Officer 1:00 pm – 1:05 pm Introduction to CorMedix Therapeutics – Creating Long-Term Value Joe Todisco, Chief Executive Officer 1:05 pm – 1:20 pm REZZAYO® (rezafungin for injection) Treatment - Disease State & Market Overview Liz Hurlburt, Chief Operating Officer 1:20 pm – 1:25 pm Redefining Treatment Through Long-Acting Innovation Expert Panel 1:25 pm – 1:45 pm REZZAYO® (rezafungin for injection) Prophy Potential - Disease State, Clinical Study, & Commercial Opportunity Pete Sullivan, PharmD, BCOP, ACE SVP, Market Access 1:45 pm – 2:00 pm Advancing Prevention - The Role of Prophylaxis in Modern Therapeutics Expert Panel 2:00 pm – 2:20 pm DefenCath® TPN - Disease State, Clinical study, & Commercial Opportunity Jared Crandon, PharmD Executive Director, Clinical Portfolio Mgmt 2:20 pm – 2:30 pm Closing the Gap - Infection Prevention as a Core Component of TPN Care Expert Panel 2:30 pm – 2:50 pm Investment Highlights & Company Milestones Joe Todisco Chief Executive Officer 2:50 pm – 3:00 pm Q&A Discussion – Clinical and Corporate Joe Todisco Liz Hurlburt 3:00 pm – 3:25 pm Closing Remarks Joe Todisco, Chief Executive Officer 3:25 pm – 3:30 pm 2026 Analyst Day I Introduction
Page 5
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 5 CorMedix Therapeutics Leadership Team PRIOR EXPERIENCEJOINED Joe Todisco Chairman & Chief Executive Officer 2022 • Chief Commercial Officer of Amneal Specialty • Co-founder and Chief Executive of Gemini Laboratories • Commercial Strategy and business development at Ranbaxy Beth Zelnick Kaufman EVP, Chief Legal and Compliance Officer, Corporate Secretary 2023 • Chief Legal Officer of Akorn Pharmaceuticals • Chief Legal Officer of The Broad Institute of MIT & Harvard • Assistant GC and Head of Government Affairs, Amneal • Actavis, Alpharma, Topcon America Liz Hurlburt EVP, Chief Operating Officer 2017 Led LOCK-IT-100 clinical study program • VP of Clinical Operations at Gemphire Therapeutics • Additional renal area experience from Rockwell Medical • Co-Founder of BRAHN (Biomedical Research Alliance at Hypertension & Nephrology LLC) Michael Seckler EVP, Chief Commercial Officer 2026 • Chief Executive Officer of Evome Medical Technologies • Chief Operating Officer of FerGene • VP, Global Marketing & Corporate Communications at Ferring Susan Blum EVP, Chief Financial Officer 2025 • CFO of Melinta (previously VP of Finance & Chief Accounting Officer at Melinta, Controller at Melinta) • VP and Controller, Textura Corporation (now Oracle) • Director, External Reporting and Revenue, PDL / Facet Matt David, MD EVP, Chief Business Officer 2020 • Previously CFO and Interim CEO of CorMedix • Head of Strategy at Ovid Therapeutics • Life science focused investment banker • Pharma research analyst at Lehman Brothers 2026 Analyst Day I Introduction
Page 6
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 6 CorMedix Therapeutics 2025 Overview 2026 Analyst Day I Introduction DefenCath saw strong results during its peak TDAPA period full year on the market ~$260M in net sales CorMedix acquired Melinta Therapeutics to add a synergistic portfolio with proven performance in the acute care setting CorMedix Therapeutics expects to go through a transformative period over the next couple of years with the introduction of new opportunities for growth that we will highlight today 2025 Pro Forma Revenue Exceeded ~$400 million* *FY 2025 Unaudited Pro Forma Net Revenue was prepared by combining the estimated financial results and for CorMedix and Melinta for the full fiscal year ended December 31, 2025, without further adjustment, as if the transaction had closed on January 1, 2025.
Page 7
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 7 CorMedix Therapeutics Has A Diverse Portfolio Of Complementary Assets Product Current Therapeutic Area Product Class CRBSI Taurolidine and heparin catheter lock solution Candidemia and invasive candidiasis Echinocandin antifungal Serious infections including Acinetobacter Tetracycline antibacterial Complicated Urinary Tract Infections (cUTIs) Carbapenems/ beta-lactamase inhibitor Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Lipoglycopeptide antibacterial ABSSSI and Community-Acquired Bacterial Pneumonia (CABP) Fluoroquinolone antibacterial Hypertension, Coronary Artery Disease, Heart Failure Beta-adrenergic blocker Hospitals & IDNs Physician Office Infusion Centers Home Infusion Long Term Acute Care Centers Shared Call Points 2026 Analyst Day I Introduction
Page 8
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 8 CorMedix Therapeutics Development Stage Pipeline Has Potential To Drive Meaningful Value Over Coming Years Product Therapeutic Area Expansion Pre-Clinical Ph I Ph II Ph III / Registrational Commercial Prophylaxis* Pneumocystis Pneumonia in HIV Adults* Chronic Pulmonary Aspergillosis* Total Parenteral Nutrition (TPN) Hemodialysis (Pediatric) Pipeline and Growth Opportunities Ph III Ph III Ph III *Study being run by Mundipharma Ph II Ph II 2026 Analyst Day I Introduction
Page 9
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 9 Financial Highlights GuidanceKey Financials Balance Sheet at December 31, 2025Key Statistics at December 31, 2025 FY 2025 Net Revenue (Pro Forma1) FY 2024 Net Revenue (CorMedix) Q4 2025 Adjusted EBITDA2 Q4 2025 Net Revenue FY 2026 DefenCath Sales FY 2026 Adjusted EBITDA2 FY 2026 Revenue Common Shares Outstanding Exchange Convertible Debt Cash and short-term investments** FY 2027 DefenCath Sales FY 2024 Net Revenue (Melinta) Q4 2025 DefenCath Sales * 2025 unaudited and preliminary financial results are based on CorMedix Therapeutics’ current expectations and may be adjust ed as a result of, among other things, the completion of our internal review process and the completion of customary annual audit procedures, ** Excludes restricted cash (1) Pro Forma Net Revenue was prepared by combining the estimated financial results and for CorMedix and Melinta for the full fiscal year ended December 31, 2025, without further adjustment, as if the transaction had closed on January 1, 2025 (2) Adjusted EBITDA is a non-GAAP financial measure and excludes non-cash items such as stock-based compensation and certain non-recurring items. The Company expects to provide a reconciliation of Adjusted EBITDA to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2025 financial results. Such reconciliation is not included herein because CorMedix is finalizing certain amounts that would be required to be included in the U.S. GAAP measure or the individual adjustments for such reconci liation. 2026 Analyst Day I Introduction $44 million $120 million ~$400 million* ~$127 million* ~$90 million* $77 – 81 million* $100 – 140 million $150 – 170 million $100 – 125 million $300 – 320 million 79.3 million NASDAQ Global Market $150 million* $148 million*
Page 10
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 10 Portfolio Trends & Future Additions $106M $151M ~$407M* $310M** • Current portfolio has a stable revenue base with opportunities to grow • CorMedix Therapeutics is pursuing organic growth opportunities to increase revenue potential REZZAYO Treatment: • TAM of $250-$350 million Prophylaxis: • TAM of >$2 billion DefenCath TPN: • TAM of $500-$750 million • In 2027, we expect to realize increased revenue from organic growth, rebound in DefenCath add-on payments and demand increase, and continued growth in current portfolio CorMedix Therapeutics Portfolio Net Sales Portfolio Highlights *FY 2025 Unaudited Pro Forma Net Sales was prepared by combining the estimated financial results and for CorMedix and Melinta for the full fiscal year ended December 31, 2025, without further adjustment, as if the transaction had closed on January 1, 2025. **2026 are forecasted numbers 2026 Analyst Day I Introduction Other Marketed Products = VABOMERE, MINOCIN, ORI, BAXDELA, TOPROL XL Peak TDAPA
Page 11
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Liz Hurlburt, Chief Operating Officer 11 REZZAYO® Treatment 2026 Analyst Day
Page 12
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 12 REZZAYO - Introduction 2026 Analyst Day I REZZAYO Treatment Rezafungin - A novel long-acting echinocandin with distinctive properties Properties Evidence Broad-spectrum activity Activity vs. Candida, Aspergillus, and Pneumocystis spp.1,2 Long-acting PK Once-weekly dosing as in Phase 3 clinical trials3,4 Front-loaded plasma drug exposure Efficacy: Shorter time to negative blood culture5,6 Observed absence of toxic degradation products Potential for less hepatotoxicity7 No clinically relevant DDIs and favorable hepatic and renal safety Compatibility with other medications8,9 Sources: 1. Pfaller MA et al. Antimicrob Agents Chemother. 2020: AAC.00099-20; 2. Cushion MT, Ashbaugh A. J Fungi (Basel). 2021;7:747; 3. ReSTORE CSR; 4. ClinicalTrials.gov. NCT04368559. Accessed October 24, 2022. https://clinicaltrials.gov/ct2/show/NCT04368559; 5. Lakota EA et al. Antimicrob Agents Chemother. 2017;61:e00758-17; 6. Soriano A et al. Presented at: European Congress of Clinical Microbiology and Infectious Diseases, Lisbon, Portugal, 23-26 April 2022. Abstract no. 04673; 7. Ong V et al. Antimicrob Agents Chemother 2022 Jan 18;66(1):e0139021 8. Flanagan S et al. Microbiol Spectr. 2023 Jun 15;11(3):e0133923. 9. Sandison T et al. Presented at: The 22nd Symposium of the International Immunocompromised Host Society (ICHS)/Annual Congress of the Swiss Society for Allergology and Immunology (SSAI) Joint Congress, Basel, Switzerland, September 8-11, 2022. Poster P13. Changes in choline moiety leads to enhanced stability Rezafungin
Page 13
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 13 REZZAYO - Clinical Development Studies 2026 Analyst Day I REZZAYO Treatment *Study sites in China are still recruiting patients for submission of rezafungin to the Center for Drug Evaluation in China. Note: IFD = Invasive Fungal Disease; mITT = Modified Intent-To-Treat Population. Sources: 1. Thompson GR et al. Clin Infect Dis. 2021;73:e3647-e3655; 2. ReSTORE CSR; Data on File, Melinta Therapeutics, LLC. 3. ClinicalTrials.gov. Accessed October 24, 2022. https://clinicaltrials.gov/ct2/show/NCT04368559 PHASE 2 Dose-Finding Study PHASE 3 Treatment Trial PHASE 3 Prophylaxis Trial STRIVE 1 ReSPECT 3 Potential Indication Treatment of invasive candidiasis and candidemia Treatment of invasive candidiasis and candidemia Prophylaxis against IFD caused by Aspergillus, Candida, and Pneumocystis in allogeneic blood and marrow transplant patients Trial Size 183 patients in mITT (Not powered for inferential statistical analysis) 187 patients in mITT (20% noninferiority margin) ~600 patients (12.5% noninferiority margin) Trial Status Complete Complete* Ongoing ProphylaxisTreatment 1 2 3
Page 14
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS An additional subset of invasive candidiasis patients do not have Candidemia that could use REZZAYO Treatment Treatment could be longer than 4 weeks for some patients Epidemiology changing and increasing azole resistance 14 REZZAYO Treatment - Opportunity 2026 Analyst Day I REZZAYO Treatment REZZAYO Treatment launched in 2023, but we believe there is untapped potential within Candidemia/Invasive Candidiasis that has yet to be fully captured Approximately 25,000 Candidemia1 cases per year leads to a sizable market opportunity for continued growth Treatment course duration is expected to be 4 weeks (which would include 5 doses) Lower treatment burden versus patients receiving a daily echinocandin leading to increased adherence Treatment Opportunity Source: 1. CDC (Data & Statistics on Candidemia) Treatment Upside The total addressable market of REZZAYO Treatment is ~$250-$350 million
Page 15
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Expert Panelists 15 REZZAYO Treatment – Expert Panel Introduction Cornelius Neil Clancy, MD Chief, Infectious Disease University of Pittsburgh Michael Mansour, MD, PhD Associate Professor of Medicine, Harvard Medical School Director, Mansour Laboratory at Massachusetts General Hospital Infectious Disease Physician & Researcher Please welcome…. 2026 Analyst Day I REZZAYO Treatment Travis King, PharmD, BCPS-AQ ID Clinical Specialist, ID Ochsner Health Moderator Liz Hurlburt Chief Operating Officer
Page 16
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Pete Sullivan, PharmD, BCOP SVP, Market Access 16 REZZAYO® Prophylaxis – Potential Indication 2026 Analyst Day
Page 17
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Why Prophy? 2026 Analyst Day I Prophylaxis 17 NCCN Guidelines recommend antifungal prophylaxis in patients with intermediate or high risk Source: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prevention and Treatment of Cancer-Related Infections V.1.2025. Accessed November 20, 2025.https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. High risk of opportunistic infection These patients require prophy for long period of time including fungal therapy Hematologic malignancies Highly immunosuppressive therapies Patients with...Patients on...
Page 18
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 18 Prophy – Treatment Journey Azoles are the standard anti-fungal prophylaxis agent for allogeneic BMT patients. Micafungin is reserved for patients with safety concerns due to more limited fungal activity 2026 Analyst Day I Prophylaxis Autologous BMTAllogeneic BMT* Prophylaxis continues until ~100 days post-transplant (longer if patient develops GVHD) Engraftment * Donor cell source may impact prophylactic regimen. ** Choice is dependent on patient’s insurance coverage. Note: BMT = Bone Marrow Transplant, DDI = Drug-Drug Interaction. Source: Health Advances interviews, survey, and analysis, NCCN Antifungal Guidelines 2024, Amonoo 2024 JAMA, Gratwohl 2015 Lancet, UpToDate. Treatment Journey ~45% ~55% Candida Specific Mold Active Prophylaxis continues until 14 days post- transplantIsavuconazole Voriconazole Elevated liver enzymes or DDI concerns Elevated liver enzymes or DDI concerns or** Post-engraftment or Patient Indicated for BMT Micafungin MicafunginPosaconazole FluconazoleFluconazole
Page 19
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Prophy – Treatment Journey A majority of patients with acute hematologic malignancies receive antifungal prophylaxis. AML patients are most likely to receive antifungal prophylaxis 2026 Analyst Day I Prophylaxis Note: DDI = Drug-Drug Interaction, ID = Infectious Disease. Source: Health Advances interviews, survey, and analysis, NCCN Antifungal Guidelines 2024, UpToDate. Hematologic Malignancies Start of Chemo Treatment Journey Duration of prophylaxis varies by clinic and is typically determined by ID specialist and/or transplant pharmacist. Candida Specific Mold Active PJP Specific Treat for Infection Only Aspergillus Posaconazole Candida Fluconazole PJP Bactrim CLLAMLALL Fluconazole MicafunginPosaconazole Elevated liver enzymes or DDI concerns 19
Page 20
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 20 Prophy – Market Opportunity * TMP-SMX (Bactrim) and pentamidine (Pentam, NebuPent) not shown due to different use case and common use as add-on therapy on top of antifungal prophylaxis options shown. Source: Health Advances survey, interviews, and analysis. 2026 Analyst Day I Prophylaxis 29% 34% 32% 31% 28% 31% 27% 28% 29% 27%26% 25% 24% 23% 19% 15% 14% 13% 14% 16% 19% 16% 15% 14% 10%8% 7% 6% 6% 5%6% 6% 4% 5% 5% 0% 20% 40% Pre-Transplant Conditioning Engraftment 1 Week Post-Transplant 1 Month Post-Transplant 3 Months Post-Transplant Share of Patients on Antifungal Prophylaxis Agent Posaconazole Fluconazole Voriconazole Isavuconazole Micafungin Caspofungin Anidulafungin 24% 32% 15% 15% 14% 33% 25% 30% 24% 28% 19% 22% 12% 9% 12% 8% 10% 7% 5% 7%8% 8% 4% 4% 5%4% 4% 2% 2% 2%1% 1% 1% 1% 0% 0% 20% 40% ALL AML MDS MM NHL Share of Patients on Antifungal Prophylaxis Agent Posaconazole Fluconazole Voriconazole Isavuconazole Micafungin Caspofungin Anidulafungin Share of Hematological Malignancy Patients Receiving Antifungal Prophylaxis Agents By Malignancy* Hem-Oncs and Hematological ID Physicians, n=75 Share of Allo-BMT Patients Receiving Antifungal Prophylaxis Agents By Timepoint* Transplant Specialists and Transplant ID Physicians, n=52 Based on our market research there was a wide variety of anti-fungal agents used that represents a large opportunity. Data is based on number of transplants per respondent
Page 21
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 21 Prophy – Market Opportunity Continued 2026 Analyst Day I Prophylaxis Share of Hematological Malignancy Patients To Whom Prophy Would Be Prescribed Hem-Oncs and Hematological ID Physicians, n=75 Share of Allo-BMT Patients To Whom Prophy Would Be Prescribed Transplant Specialists and Transplant ID Physicians, n=52 Adoption estimates ranged up to 63% amongst surveyed Transplant Specialists 50% 62% 63% 63% 52% 24% 54% 52% 52% 41% 0% 40% 80% Pre-Transplant Conditioning Engraftment 1 Week Post-Transplant 1 Month Post-Transplant 3 Months Post-Transplant Share of Patients on Antifungal Prophylaxis Agent Transplant Specialist Transplant ID 39% 44% 32% 19% 25% 52% 55% 37% 38% 43% 0% 40% 80% ALL AML MDS MM NHL Share of Patients on Antifungal Prophylaxis Agent Hem-Oncs Hem ID Question: For patients with different hematologic malignancies who are receiving antifungal prophylaxis, in what proportion would you choose to use Product X? In what proportion of patients at each of the time points related to allogeneic hematopoietic stem cell transplantation would you use Product X? Source: Health Advances interviews and analysis.
Page 22
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS T cross all hematology oncology and transplant patient usage Prophylaxis ddressa le Patient Population . . Candida spergillus P P llo uto T ther 22 Prophy – Commercial Opportunity Expands portfolio and reach into hematology/oncology and transplant markets Larger patient population, with potentially for additional addressable patients for hematological malignancies and those on highly immunosuppressive therapies Longer treatment course (13+ weeks for prophylaxis vs. 4 weeks for treatment) REZZ Y ’s la el expansion into prophylaxis could unlock an opportunity of an additional addressa le market representing a >$2B TAM Prophy Growth Opportunity 2026 Analyst Day I Prophylaxis TAM assumes REZZAYO price across this patient population Note: TAM = Total Addressable Market, Allo = Allogeneic Bone Marrow Transplant, Auto = Autologous Bone Marrow Transplant, AML = Acute Myeloid Leukemia, SOT = Solid Organ Transplant, PJP = Pneumocystis Jiroveci Pneumonia Source: Internal market research, Datamonitor, Cancer.org, bloodstemcell.hrsa.gov.
Page 23
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 23 REZZAYO - Clinical Development Studies 2026 Analyst Day I Prophylaxis Note: IFD = Invasive Fungal Disease, mITT = Modified Intent-To-Treat Population. Sources: 1. Thompson GR et al. Clin Infect Dis. 2021;73:e3647-e3655; 2. ReSTORE CSR; Data on File, Melinta Therapeutics, LLC. 3. ClinicalTrials.gov. Accessed October 24, 2022. https://clinicaltrials.gov/ct2/show/NCT04368559 PHASE 2 Dose-Finding Study PHASE 3 Treatment Trial PHASE 3 Prophylaxis Trial STRIVE 1 ReSPECT 3 Potential Indication Treatment of invasive candidiasis and candidemia Treatment of invasive candidiasis and candidemia Prophylaxis against IFD caused by Aspergillus, Candida, and Pneumocystis in allogeneic blood and marrow transplant patients Trial Size 183 patients in mITT (Not powered for inferential statistical analysis) 187 patients in mITT (20% noninferiority margin) ~600 patients (12.5% noninferiority margin) Trial Status Complete Complete* Ongoing ProphylaxisTreatment 1 2 3
Page 24
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 24 REZZAYO Prophy – ReSPECT Study • Study for the prevention of invasive fungal diseases in subjects undergoing allogeneic blood and marrow transplantation (BMT) • Primary Endpoint – Non-inferiority of Rezafungin vs. SAR for fungal-free survival at Day 90 (+/- 7 days) (FDA) – Then assess superiority of Rezafungin over SAR for fungal-free survival at Day 90 (+/- 7 days) (EMA) • Select Secondary Endpoint – Evaluate discontinuation of Rezafungin compared to the SAR secondary to toxicity or intolerance at Day 90 (+/- 7 days) • Study site locations: • Company announced completion of enrollment in late September 2025 Standard Antimicrobial Regimen (SAR) Arm US Canada Belgium France Germany Italy Spain Turkey UK 2:1 randomized double blind • 13-week treatment of Rezafungin IV • 400mg loading dose in Week 1 • 200mg once weekly • Placebo for SAR • Fluconazole (400mg QD) • Posaconazole (300mg BID D1/daily) • Trimethoprim/sulfamethoxazole (TMP/SMX) • Placebo for Rezafungin injection ReSPECT Ph III Global Multicenter Study (Data Expected Q2 2026) 2026 Analyst Day I Prophylaxis
Page 25
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Expert Panelists 25 Prophy – Expert Panel Introduction Jayastu Senapati, MBBS Assistant Professor, Dept. of Leukemia MD Anderson Cancer Center Melinda Cook, PharmD, BCOP BMT Clinical Pharmacy Specialist Memorial Sloan Kettering Cancer Center Please welcome…. Doris Ponce, MD, MS Bone Marrow Transplant Specialist Memorial Sloan Kettering Cancer Center 2026 Analyst Day I Prophylaxis Moderator Pete Sullivan, PharmD, BCOP SVP, Market Access
Page 26
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Jared Crandon, PharmD Executive Director, Clinical Portfolio Management 26 DefenCath In Total Parenteral Nutrition (TPN) 2026 Analyst Day
Page 27
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 27 CVCs Are Used In Various Acute And Long-Term Care Settings 2026 Analyst Day I DefenCath TPN Note: CVC = Central Venous Catheter. Sources: 1. United States Renal Data System. 2025 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2025. 2. Lipitz-Snyderman et al. J Clin Oncol. 2014;32(22):2351-2356. 3. Gershengorn et al. Anesthesiology. 2014;120(3):650-664. 4. Thomas DR. Total Parenteral Nutrition. https://www.merckmanuals.com/professional/nutritional-disorders/nutritional- support/total-parenteral-nutrition-tpn Condition or Setting Role in Patient Care Rate of CVC Use Kidney Disease or End Stage Kidney Disease1 Used in hemodialysis where: • One port removes blood and transports it to the dialysis machine • One port returns cleaned blood into the body ~25% Intensive Care Unit/ Critical Care Unit2,3 Deliver medication and nutrition for patients receiving longer-term inpatient, intensive care 43–80% Enable frequent blood draws for monitoring purposes Total Parenteral Nutrition4 Deliver nutrition for patients that cannot receive nutrients by mouth (eg, avoids the gastrointestinal tract) ~100%
Page 28
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 28 Complications Of Total Parenteral Nutrition 2026 Analyst Day I DefenCath TPN Central line-associated bloodstream infections1,4 • Caused by intra- or extraluminal sources • Bacterial and fungal etiologies • Significant morbidity and mortality Metabolic Abnormalities4 • Refeeding Syndrome • Hyperglycemia • Hypertriglyceridemia • Serum electrolyte abnormalities • Hepatobiliary Dysfunction Catheter-related thromboembolic/mechanical complications 1,2,3 • Clotting within the catheter lumen • Deep vein thrombosis/ Pulmonary embolism • Venous stenosis • Pneumothorax • Vascular injury Sources: 1. Napalkov et al. BMC Cardiovasc Dis. 2013;13:86. 2. Gunawansa et al. Ann Vasc Surg. 2018;51:298-305. 3. Eisen et al. J Intensive Care Med. 2006;21(1):40-46. 4. Shibila et. al. As J Pharm Res and Dev. 2023; 11(2): 65-68. 5. Schwanke et al. Rev Bras Enferm. 2018;71(3):1115-1121.
Page 29
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 29 Current CLABSI Prevention Methods 2026 Analyst Day I DefenCath TPN *Including those with long-term HD-CVCs who have a history of recurrent CLABSI, limited venous access and a history of recurrent CLABSI, or at heightened risk of severe sequelae from a CLABSI Note: CLABSI = Central Line-Associated Bloodstream Infection, CVC = Central Venous Catheter. Source: 1. Buetti et al. Infect Control Hosp Epidemiol. 2022;43(5):553-569. Hand hygiene Disinfection hubs, connectors, and ports Frequent dressing changes Chlorhexidine dressings Preventative antimicrobial lock therapy in select patients* with long-term CVCs Outside Catheter Inside Catheter
Page 30
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 30 2026 Analyst Day I DefenCath TPNTaurolidine Is A Broad-Spectrum Antimicrobial Agent • Taurolidine is non-antibiotic antimicrobial derived from the amino acid taurine1,2 • The mechanism of action of taurolidine is non-specific1 – Causes damage to microbial cell walls and inhibits adherence of microorganisms to biological surfaces – In vitro activity against most isolates of the following microorganisms1 • Taurolidine has no known resistance – In vitro bacterial serial passage studies were unable to induce resistance (>4-fold increase in MIC) after 20 passages4 Gram positive • Staphylococcus aureus (including MRSA) • Staphylococcus epidermidis • Enterococcus faecalis Gram negative • Escherichia coli • Klebsiella pneumoniae • Pseudomonas aeruginosa • Serratia marcescens Fungi • Candida albicans • Candida glabrata • Candida auris3 DefenCath Is A Catheter Lock Solution Containing Taurolidine And Heparin Note: MIC = Minimum Inhibitory Concentration. Sources: 1. DefenCath® (taurolidine and heparin) catheter lock solution Prescribing Information, CorMedix, Berkeley Heights, New Jersey. 2. Data on file, CorMedix Inc.3. Reidenberg BE, Jenkins SG, Crandon JL, et al. In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections. Antimicrob Agents Chemother. 2024;68(7):e0038124 4. Radakovic S, Andreoli N, Schmid S, Nietzsche S, Zumbrunn J, Sculean A, Eick S. Taurolidine Acts on Bacterial Virulence Factors and Does Not Induce Resistance in Periodontitis-Associated Bacteria—An In-Vitro Study. Antibiotics. 2020; 9(4):166. https://doi.org/10.3390/antibiotics9040166
Page 31
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 31 DefenCath In Total Parenteral Nutrition • Approximately 40,000 patients in the US receiving outpatient/home TPN • CLABSIs occur in up to 26% of TPN patients with a CVC • A majority of TPN patients receive daily lock therapy • Components of TPN could enhance risk of infection • A majority of these patients received TPN at home by non-healthcare personnel • Heparin locks are the current standard of care, lacking an approved and widely available antimicrobial option Note: TPN = Total Parenteral Nutrition, CLABSI = Central Line Associated Bloodstream Infection, CVC = Central Venous Catheter. Source: CorMedix Market Research, CDC, UpToDate, Ross 2016 American Journal of Infection Control, Opilla 2008 American Journal of Infection Control, Thomas Jefferson University Hospital, Beghetto 2005 Journal of Parenteral Nutrition, Duke Health, Milstone 2010 Infection Control and Hospital Epidemiology. Patient Characterization US Total Parenteral Nutrition Total Addressable Market (2024E) 1.55 3.130.25 0.51 1.80 3.64 0 1 2 3 4 Inpatient Home Total Infusions (MM) Ports or IVs CVCs, PICCs, or Midlines DefenCath Addressable Infusions ~$500-750MM Total Addressable Market TPN represents an opportunity of ~4.7MM infusions per year across outpatient and inpatient settings, an addressable market of ~$500-750MM 2026 Analyst Day I DefenCath TPN
Page 32
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 32 TPN Reimbursement 2026 Analyst Day I DefenCath TPN Commercial insurance accounts for the majority of the TPN patients Payers signal likelihood to covering DefenCath for TPN once approved DefenCath would be covered as a Medicare Part B drug Note: TPN = Total Parenteral Nutrition, DRG = Diagnostic-Related Groups. Sources: 1. National Home Infusion Association (Infusion Industry Trends, 2025) 2. Valuate survey, interviews, and analysis DefenCath to have multiple routes to reimbursement in TPN, and coverage should not be an issue Health Plans Likelihood to cover DefenCath for TPN Patients once approved2 % of respondents Payor Mix for TPN Patients1 Commercial and Medicare claims data 49% 14% 23% 10% 4% Commercial Medicare Advantage Medicare FFS + Dual Medicaid FFS + Managed Other 15% 75% 10% Very Likely Moderately Likely Not Likely
Page 33
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 33 DefenCath TPN – NUTRI-GUARD Study Program Overview: A Ph 3, randomized, double-blind, adaptive, 2-arm, study assessing the safety and efficacy of DefenCath in reducing central line-associated bloodstream infections (CLABSIs) in adult patients receiving total parenteral nutrition (TPN) via central venous catheter (CVC) Subjects 90 target; 200 max Enrollment is on-going Total Sites in the U.S. & Turkey 25 Ph 3, Duration of treatment 12 months Randomization 2:1 (60:30) To evaluate the efficacy of DefenCath in reducing the incidence of CLABSI over 12 months compared with heparin as a catheter lock solution (CLS) Primary Endpoint 2026 Analyst Day I DefenCath TPN
Page 34
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Expert Panelists 34 TPN – Expert Panel Introduction Please welcome…. Michael Owen-Michaane, MD, MA, PNS, CNSC Assistant Professor of Medicine Columbia University Irving Medical Center Elise M Brett, MD, FACE Associate Clinical Professor Division of Endocrinology, Diabetes and Bone Disease Icahn School of Medicine at Mount Sinai 2026 Analyst Day I DefenCath TPN Jason Pogue, PharmD, FIDP, FCCP Clinical Professor University of Michigan Moderator Jared Crandon, PharmD Executive Director, Clinical Portfolio Management
Page 35
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Joe Todisco, Chairman & Chief Executive Officer 35 Setting The Stage To Deliver Shareholder Value 2026 Analyst Day
Page 36
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 36 CorMedix Therapeutics Is Well Positioned To Continue To Create Value As A Diversified Specialty Pharma Business With A Compelling Growth Path Inflecting Commercial-Stage Company Strong Initial DefenCath Launch Broad Dialysis Market Penetration Durable, Diversified Revenue Streams Melinta Acquisition, Expanding Portfolio Track Record of Successfully Bringing Drugs to Market Platform for Full Suite of Institutional Products Operating at Scale High-Growth, Cash Flow Generating Business Diversified Commercial Leader Single Indication Past Diversified Portfolio with Multiple Indications & Assets Today Dynamic Institutional Platform Longer Term 2026 Analyst Day I Closing Ongoing Ph III studies Strategic BD and financial flexibility to pursue growth opportunities
Page 37
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Click to edit Master text 37 Q&A
Page 38
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 38 Thank you all for attending the CorMedix Therapeutics Analyst & Investor Day!
Page 39
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 2026 Analyst Day Appendix 39
Page 40
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 40 REZZAYO – PK Parameters 2026 Analyst Day I REZZAYO Treatment In patients with candidemia and invasive candidiasis Parameter Valuea (Mean ± SD) Exposure Day 1 Day 15 Cmax (mcg/mL)b 19.2 ± 5.9 11.8 ± 3.5 AUC0-168 (mcg∙h/mL) 827 ± 252 667 ± 224 Cmin (mcg/mL) 2.4 ± 0.9 2.2 ± 0.9 Distribution % Bound to human plasma proteins Mean estimates varied from 87.5% to 93.6% in patients Mean estimates varied from 95.6% to >98.6% in healthy adults Volume of distribution (Vd) 67 ± 28 L Elimination Clearance (CL) 0.35 ± 0.13 L/hr terminal half-life (t½) 152 ± 29 hours Metabolism Metabolic pathways Hepatic metabolism of rezafungin has not been observed. It is unlikely that rezafungin is a clinically relevant substrate of CYP450 enzymes Excretionc Major route of elimination Fecal excretion % feces 74.3% of recovered radioactivity, primarily as rezafungin % urine 25.7% of recovered radioactivity, primarily as inactive metabolites Cmax= maximum plasma concentration; Cmin= trough plasma concentration; AUC0–168h= area under the plasma concentration-time curve from time zero to 168 hours post dose a Mean ± SD b Time to Cmax is 1hr post-start of infusion (i.e., end of infusion) c Excretion studied in healthy subjects Source: 1. REZZAYO . Prescribing information. Melinta Therapeutics, LLC; 2023. Notes: • Protein binding similar to other echinocandins • Vd similar to anidulafungin and ~2x that of other echinocandins • Distribution to tissues is rapid, similar to other echinocandins
Page 41
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 41 Significant & Sustained Rezafungin Tissue Distribution In Vivo 2026 Analyst Day I REZZAYO Treatment Rat PK models Extensive tissue penetration across liver, kidney, lungs, and spleen6 1 4.14 4.62 4.33 3.87 1.09 0.609 0 1 2 3 4 5 Plasma Liver Kidney Lung Spleen Heart Brain Tissue/plasma AUC0-t ratio • Concerns exist regarding the ability of current echinocandins to reach deep-tissue infections and achieve concentrations necessary to treat Candida pathogens with higher MICs1,2 • In practice, clinicians may increase the recommended dose of current echinocandins to improve outcomes • However, increasing the recommended dose to improve penetration or efficacy has not been properly studied and may be associated with increased risks3-5 • Rezafungin provides extensive concentration in deep tissue necessary to treat Candida pathogens without the need to adjust the dose6 Sources: 1. Welte R et al. Antimicrob Agents Chemother. 2021; 65(7): e0256520; 2. Howard SJ et al. Antimicrob Agents Chemother. 2011; 55:4880–4887; 3. Cancidas (caspofungin) [product information]. Merck Sharp & Dohme LLC. Rahway, NJ. 2022.; 4. Eraxis (anidulafungin) [product information]. Pfizer. New York, NY. 2021; 5. Mycamine (micafungin) [product information]. Astellas Pharma US, Inc. Northbrook, IL. 2022.; 6. Ong V et al. Antimicrob Agents Chemother. 2017;61:e01626-16; 7. Ong V et al. Biol Blood Marrow Transplant. 2018;24:S382
Page 42
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 42 Drug Penetration And Accumulation At The Site Of Infection 2026 Analyst Day I REZZAYO Treatment Intra-abdominal candidiasis mouse model Source: 1. Zhao Y et al. Antimicrob Agents Chemother. 2017;61:e01009-17. Superior tissue penetration and accumulation within liver fungal lesions vs. micafungin At 72 hours, rezafungin drug concentrations in liver lesions were ~6 fold greater than those for micafungin. *P<0.001 Single dose rezafungin (20 mg/kg) 0 10 20 30 40 50 60 Tissue drug level (µg/g) Micafungin (5 mg/kg) 2 doses Micafungin (5 mg/kg) 3 doses * Lesion (48 h) Uninvolved/ surrounding tissue (48 h) Uninvolved/ surrounding tissue (72 h) Lesion (72 h) Uninvolved/ surrounding tissue (48 h) Lesion (48 h) Uninvolved/ surrounding tissue (72 h) Lesion (72 h) * * * Mutant prevention concentration of micafungin and rezafungin (16µg/mL)
Page 43
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Breakpoints were defined based primarily on clinical and mycological data, and were more conservative than CLSI values 43 Echinocandin MIC Breakpoints 2026 Analyst Day I REZZAYO Treatment aCurrent US FDA-approved values. bRezafungin breakpoints1 are approved by CLSI as of January 20, 2024. Note: CLSI = Clinical and Laboratory Standards Institute, FDA = Food and Drug Administration, I = Intermediate, MIC = Minimum Inhibitory Concentration, R = Resistant, S = Susceptible. Sources: 1. CLSI. Performance standards for antifungal susceptibility testing of yeasts, 3rd ed. CLSI guideline M27M44S. Clinical and Laboratory Standards Institute; 2022. 2.Locke JB et al. Antimicrob Agents Chemother. 2024 Mar 25:e0158423. Breakpoint MIC, µg/mL US FDA breakpoint sa CLSI breakpointsb Rezafungin Anidulafungin Micafungin Caspofungin Candida spp. S S I R S I R S I R S I R C. albicans ≤0.12 ≤0.25 ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 C. glabrata ≤0.12 ≤0.5 ≤0.12 0.25 ≥0.5 ≤0.06 0.12 ≥0.25 ≤0.12 0.25 ≥0.5 C. tropicalis ≤0.12 ≤0.25 ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 C. parapsilosis ≤2 ≤2 ≤2 4 ≥8 ≤2 4 ≥8 ≤2 4 ≥8 C. krusei ≤0.25 ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 ≤0.25 0.5 ≥1 C. guilliermondii ≤2 4 ≥8 ≤2 4 ≥8 ≤2 4 ≥8 C. dubliniensis ≤0.12 C. auris ≤0.5 Azole resistant organisms – C. glabrata, C. parapsilosis, C. krusei, C. auris
Page 44
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 44 2026 Analyst Day I REZZAYO Treatment Rezafungin: No Clinically Relevant Drug-Drug Interactions Study 1: Drug Interaction Study in Healthy Adults (Phase 1 Data)1 Drug Possible Mechanism Observations Suggested Action Tacrolimus CYP3A4, P-gp Cmax ↓ AUC ~15% No change in dose Repaglinide CYP2C8, OATP Cmax ↑ AUC ~15% No change in dose Metformin OCT, MATEs Cmax AUC No change in dose Rosuvastatin BCRP, OATP ↑ Cmax ~12% ↑ AUC ~15% No change in dose Pitavastatin OATP Cmax AUC No change in dose Caffeine CYP1A2 Cmax AUC No change in dose Efavirenz CYP2B6 Cmax AUC No change in dose Midazolam CYP3A Cmax AUC No change in dose Digoxin CYP2B6 Cmax AUC No change in dose Drug Possible Mechanism Observations Suggested Action Venetoclax CYP3A4 Cmax AUC No change in dose Ibrutinib CYP3A4 Cmax AUC No change in dose Mycophenolate mofetil CYP3A4, CYP3A5, CYP2C8, OATP3 Cmax AUC No change in dose Cyclosporine CYP3A4 Cmax AUC No change in dose Study 2: Drug Interaction Study in Healthy Adults (Phase 1 Data)1 Note: AUC = Area Under The Curve, BCRP = Breast Cancer Resistance Protein; Cmax = Maximum Plasma Concentration, CYP = Cytochrome P450; MATEs = Multidrug And Toxin Extrusion Protein, OATP = Organic Anion Transporting Polypeptides, OCT = Organic Cation Transporter, P-gp = P-Glycoprotein. Sources: 1. Flanagan S et al. Microbiol Spectr. 2023 Jun 15;11(3):e0133923. 2. PharmGKB. Accessed November 11, 2022. https://www.pharmgkb.org/pathway/PA165964832.
Page 45
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 45 REZZAYO Treatment – ReSTORE (Ph III) Study ReSTORE was a prospective, double-blind, randomized noninferiority phase 3 study of once-weekly intravenous REZZAYO® vs daily caspofungin for the treatment of candidemia and invasive candidiasis in patients age 18 and older.1,2 Sources:1. REZZAYO®. Prescribing information. Melinta Therapeutics, LLC; 2025. 2. Thompson GR 3rd, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401(10370):49-59. doi:10.1016/S0140-6736(22)02324-8 Isolated Candida species were similar across treatment groups2 Patient characteristics in the intent-to-treat population2 2026 Analyst Day I REZZAYO Treatment
Page 46
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 46 Beyond Candidiasis: Rezafungin Activity Against Aspergillus Species 2026 Analyst Day I REZZAYO Prophylaxis Rezafungin Demonstrates Potent In Vitro Activity Against Aspergillus Species *CLSI broth microdilution methodology was employed for MEC and MIC determination (M38-A2).2 †Clinical isolates collected internationally in the JMI Laboratories SENTRY Antimicrobial Surveillance Program (2016–2018).1 MEC90/MIC90 (µg/mL)* A. fumigatus (n=183)1† A. flavus (n=45)1† Rezafungin 0.03 0.015 Anidulafungin 0.03 0.015 Caspofungin 0.03 0.03 Micafungin 0.015 0.03 MEC90/MIC90 (µg/mL)* Azole-resistant A. fumigatus (n=31)2 A. lentulus (n=11)2 A. calidoustus (n=11)2 Rezafungin 0.12 ≤ . 0.06 Posaconazole 4 0.5 4 Voriconazole >16 8 4 Micafungin 0.06 ≤0.015 0.03 Note: CLSI = Clinical and Laboratory Standards Institute, MEC = Minimum Effective Concentration, MIC = Minimum Inhibitory Concentration. Sources: 1. Pfaller MA et al. Antimicrob Agents Chemother. 2020;64:e0009920; 2. Wiederhold NP et al. J Antimicrob Chemother. 2018;73:3063-3067.
Page 47
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 47 REZZAYO Prophy – ReSPECT Study 2026 Analyst Day I REZZAYO Prophylaxis Study design1 A Phase 3, prospective, randomized, double-blind, international, multicenter trial Study aims1 To evaluate the efficacy and safety of once-weekly IV rezafungin compared with standard of care (fluconazole or posaconazole plus TMP/SMX) to prevent IFD caused by Aspergillus, Candida, and Pneumocystis in allogeneic BMT Primary efficacy endpoint1 Fungal-free survival at Day 90 (±7 days) compared to standard of care Secondary efficacy endpoint (not inclusive)1 • Compare proven and probable IFD • Compare fungal-free survival with or without a diagnosis of clinically significant GVHD • Compare time to IFD or death • Compare mortality • Incidence of treatment emergent adverse events (safety and tolerability) • Compare discontinuation for toxicity or intolerance Sample size • 602 patients have been enrolled Note: BMT = Bone Marrow Transplant, TMP/SMX = Trimethoprim/Sulfamethoxazole, IFD = Invasive Fungal Disease, RCT = Randomized, Controlled Trial, GVHD = Graft-Versus-Host-Disease Source: 1. ClinicalTrials.gov. NCT04368559. Accessed October 24, 2022. https://clinicaltrials.gov/ct2/show/NCT04368559
Page 48
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Rezafungin Placebo Azole* Bactrim® Standard Antimicrobial Regimen (SAR) Arm 48 REZZAYO Prophy – ReSPECT Study 2026 Analyst Day I REZZAYO Prophylaxis (N≅300) 400/200 mg once weekly (N≅300) 400 mg fluconazole or 300mg posaconazole once daily* 80 mg TMP/400 mg SMX once daily *Patients with acute GVHD can be switched to posaconazole Azole placebo Bactrim® placebo Rezafungin Note: GVHD = Graft-Versus-Host Disease, TMP/SMX = Trimethoprim/Sulfamethoxazole.. Source: 1. ClinicalTrials.gov. NCT04368559. Accessed October 24, 2022. https://clinicaltrials.gov/ct2/show/NCT04368559
Page 49
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 49 REZZAYO Prophy – ReSPECT Study 2026 Analyst Day I REZZAYO Prophylaxis • Age ≥18 years • HLA-matched allogeneic BMT from a family or unrelated donor, HLA- mismatched related or unrelated donor, or haploidentical donor • Myeloablative or reduced-intensity conditioning • Adequate hepatic and renal function Selected Inclusion Criteria • Patients with suspected or diagnosed IFD within 4 weeks of screening Selected Exclusion Criteria Enrollment criteria (not inclusive) Note: HLA = Human Leukocyte Antigen, BMT = Bone Marrow Transplant, IFD = Invasive Fungal Disease, RCT = Randomized, Controlled Trial. Source: 1. ClinicalTrials.gov. NCT04368559. Accessed October 24, 2022. https://clinicaltrials.gov/ct2/show/NCT04368559
Page 50
NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS 50 2026 Analyst Day I Closing Anticipated Company Milestones 2H 2026 / 1H 2027 1H 2026 Clinical/Commercial Events • REZZAYO prophylaxis study clinical data • Medicare Advantage updates Business Updates • CorMedix Therapeutics 4Q / 2025 earnings • CorMedix Therapeutics 1Q 2026 earnings Clinical/Commercial Events • Talphera Niyad study clinical data • TPN study updates and clinical data • REZZAYO prophylaxis sNDA submission and potential approval • CMS updates for 2027 add-on payments for FFS patients Business Updates • CorMedix Therapeutics earnings and business updates